Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension

Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension

Differentiated thyroid cancer (DTC) usually has a good prognosis when treated conventionally with thyroidectomy, radioactive iodine (RAI) and thyroid-stimulating hormone suppression, but some tumors develop a resistance to RAI therapy, requiring alternative treatments. Sorafenib, lenvatinib and cabo...

Full description

Bibliographic Details
Main Authors: Anne Christine Kaae, Michael C. Kreissl, Marcus Krüger, Manfred Infanger, Daniela Grimm, Markus Wehland
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:International Journal of Molecular Sciences
Subjects:
thyroid cancer
multikinase inhibitors
sorafenib
cabozantinib
lenvatinib
adverse effects
Online Access:https://www.mdpi.com/1422-0067/22/22/12217

Internet

https://www.mdpi.com/1422-0067/22/22/12217

Similar Items